Bias, Operational Bias, and Generalizability in Phase II/III Trials.
作者信息
Freidlin Boris, Korn Edward L, Abrams Jeffrey S
机构信息
Boris Freidlin, National Cancer Institute, Bethesda, MD; Edward L. Korn, National Cancer Institute, Bethesda, MD; and Jeffrey S. Abrams, National Cancer Institute, Bethesda, MD.
出版信息
J Clin Oncol. 2018 Jul 1;36(19):1902-1904. doi: 10.1200/JCO.2017.77.0479. Epub 2018 Apr 26.
Abstract
摘要
相似文献
1
Bias, Operational Bias, and Generalizability in Phase II/III Trials.II/III期试验中的偏倚、操作偏倚及可推广性
J Clin Oncol. 2018 Jul 1;36(19):1902-1904. doi: 10.1200/JCO.2017.77.0479. Epub 2018 Apr 26.
2
[Methodological approaches of clinical studies with targeted therapies].[靶向治疗临床研究的方法学途径]
Bull Cancer. 2008 Feb;95(2):185-90. doi: 10.1684/bdc.2008.0575.
3
The role of blinded independent radiologic review in ovarian cancer clinical trials: Discerning the value.盲法独立影像学审查在卵巢癌临床试验中的作用：识别其价值。
Gynecol Oncol. 2021 May;161(2):491-495. doi: 10.1016/j.ygyno.2021.02.031. Epub 2021 Mar 13.
4
Innovation in oncology clinical trial design.肿瘤临床试验设计的创新。
Cancer Treat Rev. 2019 Mar;74:15-20. doi: 10.1016/j.ctrv.2019.01.001. Epub 2019 Jan 4.
5
Developing drugs that do not cause tumor regression.研发不会导致肿瘤消退的药物。
Clin Adv Hematol Oncol. 2003 Nov;1(11):654-5.
6
Randomized phase II trials: misleading and unreliable.随机II期试验：具有误导性且不可靠。
J Clin Oncol. 2010 Nov 1;28(31):e649-50; author reply e651-3. doi: 10.1200/JCO.2010.31.3254. Epub 2010 Sep 20.
7
New designs for the selection of treatments to be tested in randomized clinical trials.用于选择在随机临床试验中进行测试的治疗方法的新设计。
Stat Med. 1994;13(5-7):417-29. doi: 10.1002/sim.4780130506.
8
General keynote: clinical trial design.主题演讲：临床试验设计
Gynecol Oncol. 2003 Jan;88(1 Pt 2):S114-6; S122-3. doi: 10.1006/gyno.2002.6951.
9
Design issues in randomized phase II/III trials.随机化 II/III 期临床试验中的设计问题。
J Clin Oncol. 2012 Feb 20;30(6):667-71. doi: 10.1200/JCO.2011.38.5732. Epub 2012 Jan 23.
10
Clinical trials.临床试验。
Methods Mol Med. 2003;87:335-52. doi: 10.1385/1-59259-399-2:335.
引用本文的文献
1
Accrual Suspensions in Seamless Phase II/III Trials: A Review of NRG Oncology Trials.无缝衔接的II/III期试验中的应计暂停：NRG肿瘤学试验综述
JCO Oncol Adv. 2024 Dec 10;1:e2400066. doi: 10.1200/OA-24-00066. eCollection 2024.
2
Lung Cancer Clinical Trials with a Seamless Phase II/III Design: Systematic Review.采用无缝II/III期设计的肺癌临床试验：系统评价
J Clin Med. 2022 Dec 2;11(23):7176. doi: 10.3390/jcm11237176.
3
Point estimation for adaptive trial designs I: A methodological review.自适应试验设计的点估计 I：方法学综述。
Stat Med. 2023 Jan 30;42(2):122-145. doi: 10.1002/sim.9605. Epub 2022 Nov 30.
4
The effects of releasing early results from ongoing clinical trials.公布正在进行的临床试验的早期结果的影响。
Nat Commun. 2021 Feb 5;12(1):801. doi: 10.1038/s41467-021-21116-4.
本文引用的文献
1
Sample size adjustment designs with time-to-event outcomes: A caution.具有事件发生时间结局的样本量调整设计：一则警示。
Clin Trials. 2017 Dec;14(6):597-604. doi: 10.1177/1740774517724746. Epub 2017 Aug 10.
2
Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials.适应性生存试验中的样本量重新评估与假设检验
PLoS One. 2016 Feb 10;11(2):e0146465. doi: 10.1371/journal.pone.0146465. eCollection 2016.
3
When is a seamless study desirable? Case studies from different pharmaceutical sponsors.何时需要进行无缝研究？来自不同制药赞助商的案例研究。
Pharm Stat. 2014 Jul-Aug;13(4):229-37. doi: 10.1002/pst.1622. Epub 2014 May 29.
4
Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.无进展生存期与总生存期关系的建模：Ⅱ/Ⅲ 期临床试验。
Clin Cancer Res. 2013 May 15;19(10):2646-56. doi: 10.1158/1078-0432.CCR-12-2939.
5
Integrated phase II/III clinical trials in oncology: a case study.肿瘤学中的整合 II/III 期临床试验：案例研究。
Clin Trials. 2012 Dec;9(6):741-7. doi: 10.1177/1740774512464724. Epub 2012 Nov 22.
6
Design issues in randomized phase II/III trials.随机化 II/III 期临床试验中的设计问题。
J Clin Oncol. 2012 Feb 20;30(6):667-71. doi: 10.1200/JCO.2011.38.5732. Epub 2012 Jan 23.
7
Outcome--adaptive randomization: is it useful?结局适应性随机化：它有用吗？
J Clin Oncol. 2011 Feb 20;29(6):771-6. doi: 10.1200/JCO.2010.31.1423. Epub 2010 Dec 20.
8
Adaptive methods: telling "the rest of the story".自适应方法：讲述“故事的其余部分”。
J Biopharm Stat. 2010 Nov;20(6):1150-65. doi: 10.1080/10543406.2010.514457.
9
Stopping clinical trials early for benefit: impact on estimation.因有益而提前终止临床试验：对估计的影响。
Clin Trials. 2009 Apr;6(2):119-25. doi: 10.1177/1740774509102310.
10
Interim futility analysis with intermediate endpoints.采用中间终点的期中无效性分析。
Clin Trials. 2008;5(1):14-22. doi: 10.1177/1740774507086648.
Zotero 插件